Boston Scientific stock (BSX) climbs as heart-rhythm rivalry and deal risk stay in play
Boston Scientific shares rose about 1% to $92.20 Friday, outperforming a weaker healthcare sector as investors focused on pulsed-field ablation for atrial fibrillation. The company’s $14.5 billion deal to buy Penumbra and its upcoming Feb. 4 earnings report are drawing scrutiny. Johnson & Johnson posted $24.6 billion in quarterly sales and gave 2026 guidance, while Medtronic and Abbott shares fell.